European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to low inflation.

Peter Prince

2019-04-11 07:35:00 Thu ET

European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to key delays in inflation convergence. ECB President Mario Draghi maintains this dovish monetary policy stance as the central bank downgrades economic growth projections for the E.U. trade bloc from 1.7% to 1.1% as of early-2019. As the ECB pushes back the next interest rate hike, Draghi announces new expansionary monetary policy measures. These measures include another financial stimulus program for banks to boost credit supply in the Eurozone. Draghi continues to commit to the price stability mandate to ensure that inflation remains hovers below the 2% target threshold.

Due to weak capital investment, labor force participation, and economic growth in Europe, most stock market analysts expect another major delay in ECB interest rate adjustments until late-2019. In addition to the subpar economic performance of the E.U. trade bloc, ECB senior advisors need to wait for the next resolution of economic policy uncertainty around Halloween Brexit. As Halloween Brexit may come back to haunt the U.K. prime minister, Draghi has to be patient to learn more about what the May administration can deliver as a plausible alternative Brexit deal in October 2019.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

What are our proprietary alpha stock signals?

Andy Yeh Alpha

2020-09-11 10:22:00 Friday ET

What are our proprietary alpha stock signals?

AYA fintech network platform provides proprietary alpha stock signals and personal finance tools. In recent times, we have completed our fresh website up

+See More

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

John Fourier

2024-05-05 10:31:00 Sunday ET

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its

+See More

Commerce Secretary Wilbur Ross suggests that 5G remains a U.S. top technology priority in light of the Sprint-T-Mobile telecom merger.

Amy Hamilton

2018-05-04 06:29:00 Friday ET

Commerce Secretary Wilbur Ross suggests that 5G remains a U.S. top technology priority in light of the Sprint-T-Mobile telecom merger.

Commerce Secretary Wilbur Ross suggests that 5G remains a U.S. top technology priority in light of the telecom merger proposal between Sprint and T-Mobile a

+See More

The Economist digs deep into the political economy of U.S. government shutdown over 3 days in January 2018.

Apple Boston

2018-01-13 08:39:00 Saturday ET

The Economist digs deep into the political economy of U.S. government shutdown over 3 days in January 2018.

The Economist digs deep into the political economy of U.S. government shutdown over 3 days in January 2018. In more than 4 years since 2014, U.S. government

+See More

Top tech firms such as Google, Intel, and Qualcomm suspend Android services to HuaWei as the Trump administration blacklists the Chinese company.

Jonah Whanau

2019-06-01 10:33:00 Saturday ET

Top tech firms such as Google, Intel, and Qualcomm suspend Android services to HuaWei as the Trump administration blacklists the Chinese company.

Top tech firms such as Google, Intel, and Qualcomm suspend Android services to HuaWei as the Trump administration blacklists the Chinese company. HuaWei can

+See More

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an

+See More